Karolina Jendryczko
University of Wrocław
CytotoxicityDrug carrierProtein engineeringCytotoxic T cellSortaseVesicular transport proteinChemistryConjugateSortase AMonomethyl auristatin ETargeted therapyEndocytosisFibroblast growth factor receptor 1Cancer researchBiochemistryFibroblast growth factor receptorCancer cell
Publications 2
Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as growth factor receptors on their surface. This feature enables development of highly selective therapeutics, the protein bioconjugates, composed of targeting proteins (antibodies or receptor ligands) connected to highly cytotoxic drugs by a specific linker. Due to very high affinity and selectivity of targeting proteins the bioconjugates recognize ...
#1Karolina Jendryczko (UWr: University of Wrocław)
#2Julia Chudzian (UWr: University of Wrocław)H-Index: 2
Last. Anna Szlachcic (UWr: University of Wrocław)H-Index: 10
view all 8 authors...
Fibroblast growth factor receptors (FGFRs) are emerging targets for directed cancer therapy. Presented here is a new FGFR1-targeting conjugate, the peptibodyF2, which employs peptibody, a fusion of peptide and the Fc fragment of human IgG as a selective targeting agent and drug carrier. Short peptide based on FGF2 sequence was used to construct a FGFR1-targeting peptibody. We have shown that this peptide ensures specific delivery of peptibodyF2 into FGFR1-expressing cells. In order to use peptib...